Labcorp Holdings Inc.
NYSE:LHMedical - Diagnostics & Research
-$3.46 today
- Market cap
- $30.11B
- Beta
- 0.88
- P/E (TTM)
- 22.4
- EPS (TTM)
- $11.44
- Dividend yield
- 1.12%
Volume 0.69M
Average 0.63M
LH Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Labcorp Holdings Inc.NYSE: LH
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables turns negative
Q2 FY2026 accounts receivables was -$59.2M, compared with $31.8M a year earlier. Trailing-twelve-month accounts receivables was -$240.4M.
Context
- Accounts receivables amounted to 0.9% of revenue in FY2025, up 0.1 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$59.2M or moves back toward the trailing-twelve-month quarterly average of -$60.1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (122.2M) USD
- Year-over-year change
- -224.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (122.2M) | -224.1% |
| FY2024 | 2024-12-31 | 98.5M | +230.8% |
| FY2023 | 2023-12-31 | (75.3M) | -573.6% |
| FY2022 | 2022-12-31 | 15.9M | -92.8% |
| FY2021 | 2021-12-31 | 222M | — |
Accounts Receivables vs competitors
How LH compares with its peers on the latest reported figures
- LH's LTM Jun 2026 accounts receivables of $240.4M is the 2nd largest of the 7 companies compared; the peer median is $38.96M.
- Its year-over-year change of -2961.9% is the lowest of 7, against a peer median of +85.6%.
- Accounts receivables amounts to 1.7% of revenue for LH, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $261M | +210.7% | — | 2.2% | |
| LTM Jun 2026 | $240.4M | -2961.9% | — | 1.7% | |
| LTM Jun 2026 | $109.63M | -510.4% | — | 4.0% | |
| LTM Sep 2026 | $70.6M | +155.1% | — | 5.5% | |
| LTM Jun 2026 | $7.31M | -67.7% | — | 0.3% | |
| LTM Jun 2026 | $5.68M | +71.1% | — | 3.4% | |
| LTM Sep 2026 | $0 | +100.0% | -0.3% | 0.0% | |
| Peer median (excluding LH) | $38.96M | +85.6% | -0.3% | 2.8% | |
Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.38B | 1B | 379.2M | 746M | 877.7M |
| Depreciation & Amortization | 577M | 537.2M | 577.3M | 643.5M | 681.1M |
| Deferred Income Tax | (37.3M) | 26.3M | (78.1M) | (20.1M) | 97.6M |
| Stock-Based Compensation | 132.9M | 116.8M | 128.7M | 116.7M | 125.8M |
| Change in Working Capital | (263.7M) | (603.4M) | (361.9M) | (154.1M) | (526.1M) |
| Accounts Receivables | 222M | 15.9M | (75.3M) | 98.5M | (122.2M) |
| Inventory | 2.8M | (45.5M) | (700K) | (14.6M) | (30.2M) |
| Accounts Payables | (10.2M) | 307.1M | (42.4M) | 210.3M | (52.8M) |
| Other Working Capital | (478.3M) | (880.9M) | (243.5M) | (448.3M) | (320.9M) |
| Other Non-Cash Items | 321.2M | 875.5M | 682.5M | 253.8M | 384.4M |
| Operating Cash Flow | 3.11B | 1.96B | 1.33B | 1.59B | 1.64B |
| Capital Expenditures | (460.4M) | (481.9M) | (453.6M) | (489.9M) | (434.5M) |
| Acquisitions (Net) | (496.9M) | (1.16B) | (671.5M) | (823.9M) | (582M) |
| Purchases of Investments | (27.8M) | (17.4M) | (29M) | (55M) | (192.4M) |
| Sales of Investments | 13.2M | 8.1M | 6.7M | 0 | 6.9M |
| Other Investing Activities | 87.3M | 1.4M | (24.1M) | 2M | 8M |
| Investing Cash Flow | (884.6M) | (1.65B) | (1.17B) | (1.37B) | (1.19B) |
| Debt Repayment | (375M) | 0 | (300M) | 1B | (775M) |
| Common Stock Issued | 51.7M | 50.6M | 0 | 0 | 54.3M |
| Common Stock Repurchased | (1.67B) | (1.15B) | (1.04B) | (250.1M) | (450M) |
| Dividends Paid | 0 | (195.2M) | (254M) | (243.1M) | (240.7M) |
| Other Financing Activities | (74M) | 23.6M | 1.53B | 273.1M | (45.6M) |
| Financing Cash Flow | (2.07B) | (1.32B) | (59.3M) | 779.9M | (1.46B) |
| Effect of Forex Changes | (7.3M) | (24.2M) | 9.9M | (17M) | 24.1M |
| Net Change in Cash | 151.9M | (1.04B) | 106.8M | 981.9M | (986.4M) |
| Free Cash Flow | 2.65B | 1.47B | 874.1M | 1.1B | 1.21B |
Labcorp Holdings Inc.
NYSE:LH
Intrinsic Alpha fair value
Locked
Current Price
$370.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.